| 1 Opening Speech & China Biotech Innovation – Jeffrey Zhang, Chair (CHBD) 开幕致辞 & 中国生物技术创新 – 张继国 (CHBD, 会长) |
2
Cross-border Licensing Annual review – Sean Jiang, CEO (YAFO Capital)
医药跨境交易年度汇总 – 蒋晓阳 (雅法资本, CEO)
3
| New Era of Innovation and Differentiation Jiaxi Xu, Chief Pharmaceutical Analyst (Industrial Securities) 创新与差异化的新时代 徐佳熹 (兴业证券, 医药行业首席分析师) |
| 4 Bio Century Commercial Section- The Evolution of China Pharma Market Tina Hou, Global Partner (Mckinsey) 中国医药市场的演变 侯蕾 (麦肯锡, 全球合伙人) |
| 5 Global Transaction Experience – MNC Perspective Cynthia Wang, BD&Licensing Director (Servier) 全球医药交易经验-跨国药企角度分享 王昕 (施维雅, 亚太生物创新中心业务拓展及许可总监) |
| 6 Japan Market Opportunity for Chinese Pharmas Steve Engen, Founder & President (Renexes) 中国制药公司在日本市场机会 Steve Engen (Renexes, 创始人&主席) |
| 7 Investment Strategy for the Pharmaceutical Industry: Innovation + Import Substitution Lead the Great Era of Pharmaceuticals Xiangyang Du, Chief Pharmaceutical Analyst (South West Securities) 双循环背景下，创新升级+进口替代引领医药大时代 杜向阳 (西南证券, 医药行业首席分析师) |
| 8 Pharma BD in China Kui Wang, Secretary General (CHBD)BD的一段到九段修炼 汪奎 (CHBD, 秘书长) |
BioToChina.org 